Introduction and Objectives
The aim of the study was to assess PAX-5 gene expression level in Ta,T1 urothelial urinary bladder carcinoma and to find out its prognostic value.
Material and Methods
147 patients with Ta,T1 urothelial urinary bladder carcinoma have been enrolled into the study so far. The PAX-5 expression was evaluated quantitatively by realtime PCR metod using ABI PRISM 7000. As a reference gene the GAPDH gene was used, mRNA and cDNA were isolated by OLIGOTEX Metod using kits (Qiagen) and High Capacity cDNA Archive kit (Applied Biosystéme). All the patients were followed afterwards and treated following common schemes, the follow up time was 23.88±10.36 months.
Tumor recurrence was detected in 78 (53 %) patients. In a group of 82 patients with PAX5 positivity higher than 0, (PAX5 > 0, PAX5 positive group) the tumor recurrence was detected in 78 (53 %) patients. In the other group of 65 patients with zero PAX5 expression (PAX5 = 0, PAX5 negative group) the tumor recurrence was detected in only 28 patients (43.1 %). The patients with the PAX5 expression higher than 0 were of 1.7 higher tumor recurrence risk than the patients with the zero PAX5 expression. The invasive form of the tumor was detected in 12 patients (8.2 %). In the group of 147 patients, the number of tumor progression was very low, so it was not possible to define the PFI. Following the multivariant Cox model of proportional risks, the variables were PAX5 expression, clinical tumor stage, tumor grade, multiplicity and tumor size. The PAX5 expression and tumor multiplicity were only independent tumor recurrence predictors. It was not possible to predict the tumor progression risk because of a low number of progression cases.
In a big group of patients we have confirmed the prognostic significance of PAX5 gene expression when predicting the Ta,T1 urinary bladder carcinoma recurrence risk. This prediction was independent of clinical prognostic factors used in every day.
The study was supported by IGA MZ NR 8934–3 a VZ MSM 0021620808 grants.
© 2009 European Association of Urology. Published by Elsevier Inc. All rights reserved.